Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial
Fig 5
Association of HI seroprotection rate after 28(+7) days post 2nd dose administration with prior receipt of seasonal influenza vaccine, per protocol analysis.